Aldara Keratosis Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
3M's Aldara supplemental NDA cleared FDA March 2 for the treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults
You may also be interested in...
PhotoCure/Galderma Actinic Keratosis Phototherapy Clears FDA
The PhotoCure product, marketed as Metvix outside the U.S., will be launched by partner Galderma in “several weeks” following selection of an alternate tradename. The methyl aminolevulinate cream is used in combination with the CureLight activation lamp.
PhotoCure/Galderma Actinic Keratosis Phototherapy Clears FDA
The PhotoCure product, marketed as Metvix outside the U.S., will be launched by partner Galderma in “several weeks” following selection of an alternate tradename. The methyl aminolevulinate cream is used in combination with the CureLight activation lamp.
Aldara For Basal Cell Carcinoma
3M's Aldara received a supplemental approval for the treatment of superficial basal cell carcinoma July 14